Investor Presentation
Equity Forum - German Spring Conference 2022
23rd May 2022
Disclaimer
This presentation (the "Presentation") was prepared by Marinomed Biotech AG.
The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this
Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.
Certain statements contained in this document may be statements of future expectations and other forward looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.
Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.
This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.
By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.
© Marinomed Biotech AG | 2 |
Marinomed investment highlights
Transforming lives of people living with diseases with limited or no treatment options
- Management team with 100+ years of experience in biopharma with track record spanning from invention to commercialization
- Short term growth perspective with existing product portfolio
- Therapies for diseases with unmet medical need in the therapeutic areas of virology and immunology
- Lean and efficient business model - generation of IP and early clinical data to facilitate partnering with milestones and royalties
- Sustainable therapies: Strong reduction of API results in efficacious therapies with reduced systemic exposure and environmental contamination
© Marinomed Biotech AG | 3 |
Marinomed management and ownership
Total number of shares | ||
13.7% | 1,496,287 | |
8.4% | Acropora Beteiligungs GmbH | |
8.1% | ||
Dr. Hermann Unger | ||
61.7% | 8.1% | DI Dr. Andreas Grassauer (CEO) | |
Mag. Dr. Eva Prieschl-Grassauer (CSO) | |||
Free Float | |||
Profound leadership team with 100+ years of relevant industry expertise
Left to right:
Pascal Schmidt, CFO; Eva Prieschl-Grassauer, CSO and co-founder; Cornelia Kutzer, CBO, Andreas Grassauer, CEO and co-founder
© Marinomed Biotech AG | Note: Rounding differences possible | 4 |
Marinomed at a glance
Unmet
Lean, public company with track record of successfully inventing, partnering and marketing products creating sustainable value for patients and stakeholders
Committed to
ESG
Company
Founded
in 2006
First product on the
market in 2008
Marinomed IPO
in 2019
Sustainable
therapies
Increase of solubility and improved bioavailability allows significant reduction of API resulting in reduced environmental contamination.
Antiviral drugs based
on renewable raw
materials
medical need
Focus on rare diseases such as herpetic stromal keratitis, the leading cause of infectious blindness in developed countries1
Virology
Immunology
Successful
partnering
Virology:
6 products with >25 M units
sold in 40+ countries
Immunology:
First licence deal
Solv4U: performs feasibility
studies for external
partners
© Marinomed Biotech AG | 1Akbari et al., J Opthalmic Vis Res (2019); 14: 400 | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Marinomed Biotech AG published this content on 23 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2022 09:25:06 UTC.